



Press Release

Eurocor presents the latest development in second-generation, drug-eluting PTA balloon technology.

The Bonn-based company is set to launch its solutions for treating peripheral arterial disease (PAD) in Germany.

Bonn, 06th January 2011 – The Bonn-based company Eurocor GmbH will be presenting its latest development in second-generation PTA balloon technology – FREEWAY 014™ and FREEWAY 035™ – to the German market for the very first time at the LINC (Leipzig Interventional Course) on 20 January 2011. The two new products already premiered in London in November 2010.

The German launch of Eurocor's new FREEWAY products is scheduled to take place at the "Symposium on drug-coated balloons for peripheral interventions: SFA and below the knee". Under the aegis of Eurocor, international experts will be presenting and discussing the latest developments in connection with treatment involving drug-eluting balloons at this symposium.

Expert Discussion

The scientific debate will be headed by the renowned physician and consultant angiologist from Berlin, Prof. Dr. Karl-Ludwig Schulte. Presentations will include a live transmission of an intervention involving a drug-eluting balloon as well as a paper delivered by the cell biologist PD Dr. Kirsten Peters from Rostock on the unique new coating technology. Lectures by other well-known physicians on the advantages of drug-eluting balloons to treat various indications,



including below-the-knee dilations, will go to round off the programme.

Alternative to Amputation

FREEWAY 014™ was primarily developed for treating critical limb ischaemia associated with peripheral arterial disease (PAD). The primary amputation rate among diabetes mellitus patients with critical limb ischaemia linked to PAD can amount to as much as 40%. Thanks to Eurocor's FREEWAY® DEB balloon interventionalists now have access to a treatment option that constitutes a valid alternative to amputation and can additionally help to save up to US\$50,000 per patient per year.

“We are delighted to be able to present our latest developments to a large specialist audience in Leipzig. FREEWAY is the next logical step of our successful Eurocor technologies.”, said Katja Hausner, Director Business Affairs at Eurocor.

**The company**

Eurocor GmbH is a rapidly growing European Life Sciences Technology corporation specialising in the research, development and manufacture of interventional cardiology products. Eurocor is providing interventional cardiologists with innovative, coronary stent technologies and special cardiovascular devices.

The products manufactured by the company in Bonn are used in minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Strong research and development, close collaboration with clinicians, outstanding quality standard philosophy and global scientific alliances lead to optimisation of clinically effective technologies. For more information, please visit www.eurocor.de.

Werden Sie ein Follower von http://twitter.com/Eurocor_Germany

Sie finden uns auch auf Facebook. Werden Sie ein Fan.

Pressekontakt:

Blattwerk – Kommunikation für Unternehmen

Mittelweg 177

20149 Hamburg

Telefon: 040-41537634

E-Mail: eurocor@blattwerk-kommunikation.de